APA (7th ed.) Citation

B, G., MN, H., JS, d. G., L, R., S, T., & BO, F. (2021). High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. ESMO open, 6(3), 100107. https://doi.org/10.1016/j.esmoop.2021.100107

Chicago Style (17th ed.) Citation

B, Gülave, Hew MN, de Groot JS, Rodwell L, Teerenstra S, and Fabriek BO. "High Body Mass Index and Pre-existing Autoimmune Disease Are Associated with an Increased Risk of Immune-related Adverse Events in Cancer Patients Treated with PD-(L)1 Inhibitors Across Different Solid Tumors." ESMO Open 6, no. 3 (2021): 100107. https://doi.org/10.1016/j.esmoop.2021.100107.

MLA (9th ed.) Citation

B, Gülave, et al. "High Body Mass Index and Pre-existing Autoimmune Disease Are Associated with an Increased Risk of Immune-related Adverse Events in Cancer Patients Treated with PD-(L)1 Inhibitors Across Different Solid Tumors." ESMO Open, vol. 6, no. 3, 2021, p. 100107, https://doi.org/10.1016/j.esmoop.2021.100107.